Compare · NVO vs TRAW
NVO vs TRAW
Side-by-side comparison of Novo Nordisk A/S (NVO) and Traws Pharma Inc. (TRAW): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both NVO and TRAW operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $191.15B, about 10093.1x TRAW ($18.9M).
- Over the past year, NVO is down 44.9% and TRAW is down 33.5% - TRAW leads by 11.4 points.
- Both names hit the wire about 8 times in the past 4 weeks.
- NVO has more recent analyst coverage (25 ratings vs 1 for TRAW).
- Company
- Novo Nordisk A/S
- Traws Pharma Inc.
- Price
- $43.38+1.37%
- $1.25-0.79%
- Market cap
- $191.15B
- $18.9M
- 1M return
- -7.75%
- -26.04%
- 1Y return
- -44.93%
- -33.51%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NASDAQ
- IPO
- 2013
- News (4w)
- 8
- 8
- Recent ratings
- 25
- 1
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care
Latest TRAW
- SEC Form DEFA14A filed by Traws Pharma Inc.
- SEC Form DEF 14A filed by Traws Pharma Inc.
- Traws Pharma Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Traws Pharma Announces Antiviral Program Targeting Ongoing Hantavirus and Ebola Virus Disease Outbreaks
- Traws Pharma Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- SEC Form 424B5 filed by Traws Pharma Inc.
- SEC Form PRE 14A filed by Traws Pharma Inc.
- SEC Form EFFECT filed by Traws Pharma Inc.
- SEC Form 424B3 filed by Traws Pharma Inc.
- SEC Form 10-Q filed by Traws Pharma Inc.